REGENXBIO Q2 financial results and operational highlights on August 7, 2025.

• REGENXBIO to host conference call on August 7 • Discussing Q2 2025 financial results and operational highlights • Analysts can dial in for Q&A session • Webcast will be available on the company's investor website • Focus on gene therapy and AAV gene therapy research • Company founded in 2009 and on a mission to improve lives through gene therapy.

REGENXBIO Inc. (Nasdaq: RGNX), a pioneering biotechnology company specializing in gene therapy, has scheduled a conference call for Thursday, August 7, 2025, at 8:00 a.m. ET. The call will discuss the company's second quarter 2025 financial results and operational highlights. Analysts and investors are invited to participate in the Q&A session [1].

The conference call will be webcast and can be accessed through a registration link. Analysts can dial in for the Q&A session by calling (646) 307-1963 (domestic) or (800) 715-9871 (international) with the passcode 9571992. A replay of the webcast will be available on REGENXBIO's investor website approximately two hours after the call concludes [2].

REGENXBIO, founded in 2009, is on a mission to improve lives through the curative potential of gene therapy. The company has developed a late-stage pipeline of one-time treatments for rare and retinal diseases, including RGX-202 for Duchenne muscular dystrophy (DMD), clemidsogene lanparvovec (RGX-121) for mucopolysaccharidosis type II (MPS II), and surabgene lomparvovec (ABBV-RGX-314) for wet age-related macular degeneration (wet AMD) and diabetic retinopathy, in collaboration with AbbVie [3].

The company's stock has been trading at $8.50 as of July 16th, with a market cap below $100 million despite over $420 million in pro forma cash. Despite the company's strong assets and revenue streams, such as royalties from Novartis' Zolgensma, the stock trades at a distressed valuation due to broader biotech malaise and heightened uncertainty under the Trump administration's FDA appointments [3].

The core investment thesis centers on REGENXBIO's partnership with AbbVie on RGX-314, which recently expanded into diabetic retinopathy, triggering a $200 million milestone. Positive Phase II data showed a 97% reduction in rescue treatments, with pivotal data due in 2026 [3].

REGENXBIO's stock has been on a rollercoaster, with a significant drop in value over the past year. Despite this, the company's pipeline and partnerships with major pharmaceutical companies offer promising prospects for investors [4].

References:
[1] https://www.stocktitan.net/news/RGNX/regenxbio-to-host-conference-call-on-august-7-to-discuss-second-c00n47c2hdiy.html
[2] https://www.marketscreener.com/news/regenxbio-to-host-conference-call-on-august-7-to-discuss-second-quarter-2025-financial-results-and-o-ce7c5fddd88cfe21
[3] https://finance.yahoo.com/news/regenxbio-inc-rgnx-bull-case-125548712.html
[4] https://finimize.com/content/fdmt-asset-snapshot